Statistics on Biotechnology Use  
Results by fields of operation
Total Sectors. Biotechnology indicators by execution sector.
Unidades: 

;Total 2021;Companies;P.A.;Higher Education;PNPI;
Companies that perform R+D in Biotechnology;1.498;1.299;120;66;13;
%Companies according to biotechnology used: Genetic code;38;30,8;87,5;89,4;46,2;
%Companies according to biotechnology used: Functional Companies;45;38,4;88,3;93,9;53,8;
%Companies according to biotechnology used: Cellular and tissue culturing and engineering;28,9;21,5;73,3;86,4;61,5;
%Companies according to biotechnology used: Bioprocesses;53,4;50,8;58,3;93,9;69,2;
%Companies according to biotechnology used: Sub-cellular organisms;15,2;8,5;53,3;74,2;38,5;
%Companies according to biotechnology used: Bio-computing;30,8;24;73,3;87,9;30,8;
%Companies according to biotechnology used: Nanobiotechnology;18,2;12,1;54,2;72,7;15,4;
%Companies according to biotechnology used: Other;15,3;16,9;3,3;7,6;0;
Companies in which biotechnology activities are:  Main and/or exclusive;603;559;31;3;10;
Companies in which biotechnology activities are: A secondary line of business;318;230;41;46;1;
Companies in which biotechnology activities are: A tool necessary for production;577;510;48;17;2;
%Companies by field(s) of ultimate application of biotechnology use: Human health;50,4;45,5;76,7;95,5;69,2;
%Companies by field(s) of ultimate application of biotechnology use: Animal Health and Aquaculture;18,1;15,5;17,5;69,7;23,1;
%Companies by field(s) of ultimate application of biotechnology use: Food products;33,6;32,3;24,2;81,8;7,7;
%Companies by field(s) of ultimate application of biotechnology use: Agriculture and forest production;25,8;23,8;22,5;72,7;23,1;
%Companies by field(s) of ultimate application of biotechnology use: Environment;19,1;15,6;25,8;78,8;7,7;
%Companies by field(s) of ultimate application of biotechnology use: Industry;16,1;13,7;14,2;68,2;7,7;
Personnel in R&D in biotechnology (no. of persons);47.150;15.750;15.418;15.757;225;
Personnel in R&D in biotechnology (no. of persons): Research personnel;30.817;8.379;9.510;12.778;150;
Personnel in R&D in biotechnology (no. of persons): Technical and auxiliary personnel;16.333;7.371;5.908;2.979;75;
Personnel in R&D in biotechnology (no. of persons). Women;26.632;8.711;9.684;8.101;136;
Personnel in R&D in biotechnology (no. of persons). Women. Research personnel;16.540;4.510;5.637;6.314;79;
Personnel in R&D in biotechnology (no. of persons). Women. Technical and auxiliary personnel;10.091;4.200;4.047;1.787;57;
Personnel in R&D in biotechnology (FTE);32.901,7;11.528,6;11.271,7;9.934,5;166,9;
Personnel in R&D in biotechnology (FTE): Research personnel;20.945,8;6.342,7;6.454,3;8.036;112,8;
Personnel in R&D in biotechnology (FTE): Technical and auxiliary personnel;11.955,9;5.185,9;4.817,4;1.898,5;54,1;
Personnel in R&D in biotechnology (FTE). Women;18.952,5;6.539,7;7.077,3;5.228;107,5;
Personnel in R&D in biotechnology (FTE). Women: Research personnel;11.337,3;3.455,7;3.786,8;4.032,9;61,9;
Personnel in R&D in biotechnology (FTE). Women: Technical and auxiliary personnel;7.615,2;3.084;3.290,5;1.195,1;45,6;
Internal expenditure on R&D (thousands of euros);2.269.946;1.038.582;716.877;500.703;13.783;
1) By nature of the expense: Current expenses;2.087.088;940.091;672.607;461.216;13.174;
1.1) Remuneration to research personnel;872.195;321.570;252.863;293.131;4.630;
1.2) Remuneration to technicians and auxiliary personnel;384.422;194.836;128.640;59.408;1.538;
1.3) Other current expenses;830.471;423.685;291.103;108.677;7.006;
2) By nature of the expense: Capital expenses;182.858;98.492;44.270;39.487;610;
2.1) Land and buildings;20.307;10.199;2.712;7.373;23;
2.2) Equipment and instruments;144.143;72.584;40.235;30.775;549;
2.3) Acquisition of specific R+D software;8.159;5.721;1.102;1.303;33;
2.4) Otros productos de propiedad intelectual específicos para I+D;10.250;9.987;222;36;5;
1.1) By origin of the funds: Own funds;891.566;711.488;88.338;88.167;3.574;
1.2) By origin of the funds: From companies;248.128;121.738;97.993;25.096;3.301;
1.3) By origin of the funds: Public Administration funds;882.585;107.477;430.689;342.018;2.402;
1.4) By origin of the funds: From Universities;3.851;192;1.388;2.220;50;
1.5) By origin of the funds: From non profit private institutions;47.810;10.756;26.599;7.719;2.737;
1.6) By origin of the funds: Foreign funds;196.006;86.931;71.871;35.483;1.720;
Purchase of services R & D in Biotechnology to (thousands of euros);174.934;145.557;23.461;3.058;2.858;
Purchase of services R & D in Biotechnology to (thousands of euros): in Spain;123.461;95.915;21.807;3.035;2.704;
Purchase of services R & D in Biotechnology to (thousands of euros): Abroad;51.472;49.642;1.654;23;154;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to capital;43;40,2;63,3;57,6;61,5;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to technology / information;12,5;13,2;6,7;9,1;15,4;
%Companies that consider the following obstacles as very important considering biotechnology development: Access to human resources;22,1;19;45;40,9;23,1;
%Companies that consider the following obstacles as very important considering biotechnology development: Disconnection from the value chain;13,6;11,5;26,7;33,3;7,7;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of access to international markets;18,2;15,9;30;42,4;15,4;
%Companies that consider the following obstacles as very important considering biotechnology development: Lack of distribution and marketing channels;18,9;17;27,5;39,4;30,8;
%Companies that consider the following obstacles as very important considering biotechnology development: Acceptance / public perception;15,9;16,4;10;12,1;30,8;
%Companies that consider the following obstacles as very important considering biotechnology development: Legal and regulatory requirements;40,5;40,5;40;37,9;61,5;
%Companies that consider the following obstacles as very important considering biotechnology development: Time / cost;55,4;55;58,3;57,6;61,5;
%Companies that consider the following obstacles as very important considering biotechnology development: Difficulty accessing patenting;21,9;21,9;24,2;18,2;23,1;
Notas:
'..'=data not available 

 '.'=numeric piece of data equal to zero not resulting from rounding 

 FTE: Full Time Equivalent 

 (*) Total calculated from the total number of companies with related activities  with Biotechnology and the total Companies from other sectors with activities  in R&D in Biotechnology
Fuente: National Statistics Institute